髄膜炎菌ワクチンの世界市場

髄膜炎菌ワクチンの世界市場は2030年までに54億米ドルに達する

2024年に41億米ドルと推定される髄膜炎菌ワクチンの世界市場は、2024～2030年の分析期間においてCAGR 4.8%で成長し、2030年には54億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである4価ワクチンは、CAGR 5.1%を記録し、分析期間終了時には31億米ドルに達すると予測されます。二価ワクチンセグメントの成長率は、分析期間中CAGR 4.6%と推定されます。

米国市場は11億米ドル、中国はCAGR4.5%で成長すると予測

米国の髄膜炎菌ワクチン市場は、2024年に11億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに8億4,970万米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは4.5%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ4.7%と3.8%と予測されています。欧州では、ドイツがCAGR 4.1%で成長すると予測されています。

世界の髄膜炎菌ワクチン市場- 主要動向と促進要因まとめ

髄膜炎菌ワクチンとは何か、なぜ重要なのか？

髄膜炎菌ワクチンは、髄膜炎やその他の重篤な感染症を引き起こす髄膜炎菌と闘います。これらのワクチンは、特に細菌性髄膜炎が流行している地域において、これらの死に至る可能性のある病気を予防するための重要な公衆衛生手段です。髄膜炎菌ワクチンは、様々な製剤で入手可能であり、複数の血清群の髄膜炎菌を予防することで、多様な集団に対する免疫の幅を広げています。髄膜炎菌性疾患は急速に発症し重症化することが知られているため、このワクチンは人命を救うだけでなく、これらの感染症の治療にかかる医療費も大幅に削減します。世界中の公衆衛生キャンペーンや予防接種プログラムでは、アウトブレイクを抑制し、リスクのある集団を保護する上で、これらのワクチンの重要性が強調されています。

世界ヘルスへの取り組みは、髄膜炎菌ワクチンの需要にどのような影響を与えていますか？

世界ヘルスへの取り組みは、髄膜炎菌ワクチンの需要に大きな影響を与えています。世界保健機関（WHO）やGlobal Alliance for Vaccines and Immunization（GAVI）などの組織が調整するプログラムは、特に疾病負担の大きいサハラ以南のアフリカなど、十分なサービスを受けていない地域でのワクチン接種を増やすことを目的としています。このような取り組みは、髄膜炎菌ワクチンの広範な投与に役立っており、病気の蔓延を抑制しています。さらに、髄膜炎菌性疾患の発生は、集団予防接種キャンペーンという即時対応を促すことが多く、疫学的動向がワクチン需要に直接影響を与えることを物語っています。髄膜炎菌感染症に対する意識の高まりとワクチンの有効性が証明されたことも、発展途上国と先進国の両方でのワクチン摂取を促進しています。

髄膜炎菌ワクチンに影響を与える科学技術の進歩とは？

科学技術の進歩は、髄膜炎菌ワクチンの有効性と普及率を高めています。バイオテクノロジーの開発により、結合型ワクチンの開発が可能になり、免疫の持続時間が長くなり、若年層でより強い免疫反応が得られるようになりました。新しいワクチン製剤の調査により、髄膜炎菌の新たな株に対する防御が拡大し続けています。また、ワクチンの製造と保管における技術的な改善により、流通網を拡大し、遠隔地により効果的にワクチンを届けることが可能になりました。このような進歩は、特に低資源環境において世界の供給網を維持し、髄膜炎菌性疾患の撲滅に不可欠なワクチン接種率全体を向上させるために不可欠です。

髄膜炎菌ワクチン市場の成長の原動力は？

髄膜炎菌ワクチン市場の成長は、世界のヘルスケアイニシアチブの増加、病気に対する意識の高まり、国家予防接種プログラムの実施など、いくつかの要因によってもたらされます。ワクチンの有効性や生産能力を向上させる技術の進歩も重要な役割を果たしています。予防接種率の向上は、アウトブレイクに対する公衆衛生上の対応と相まって、ワクチン需要をさらに刺激しています。さらに、ワクチンの研究開発に対する政府の資金援助や国際的な支援は、進化する病原体の状況に対応し、継続的な適応と新型株に対する防御を確保するために極めて重要です。特に新興国では、意識とヘルスケアのインフラが改善されるにつれて、髄膜炎菌ワクチンに対する需要が増加し、市場拡大の原動力となることが予想されます。

セグメント

タイプ（4価、2価、その他のタイプ）、血清型（A型、B型、C型、W-135型、その他の血清型）、年齢層（乳児（2歳まで）、小児（2歳以上）、成人）

調査対象企業の例（全42件）

• Baxter International, Inc.
• Bio-Med Pvt., Ltd.
• GlaxoSmithKline PLC
• Pfizer, Inc.
• Sanofi SA
• Serum Institute of India Pvt., Ltd.

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• その他欧州
• アジア太平洋
• その他の地域

第4章 競合

Global Meningococcal Vaccines Market to Reach US$5.4 Billion by 2030

The global market for Meningococcal Vaccines estimated at US$4.1 Billion in the year 2024, is expected to reach US$5.4 Billion by 2030, growing at a CAGR of 4.8% over the analysis period 2024-2030. Quadrivalent Vaccines, one of the segments analyzed in the report, is expected to record a 5.1% CAGR and reach US$3.1 Billion by the end of the analysis period. Growth in the Bivalent Vaccines segment is estimated at 4.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.1 Billion While China is Forecast to Grow at 4.5% CAGR

The Meningococcal Vaccines market in the U.S. is estimated at US$1.1 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$849.7 Million by the year 2030 trailing a CAGR of 4.5% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 4.7% and 3.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.1% CAGR.

Global Meningococcal Vaccines Market - Key Trends & Drivers Summarized

What Are Meningococcal Vaccines, and Why Are They Critical?

Meningococcal vaccines combat the Neisseria meningitidis bacterium, which causes meningitis and other severe infections. These vaccines are crucial public health tools for preventing these potentially deadly diseases, particularly in regions where bacterial meningitis is prevalent. The vaccines are available in different formulations, including those that protect against multiple serogroups of the bacterium, thereby broadening immunity across diverse populations. With meningococcal disease known for its rapid onset and severity, the vaccines not only save lives but also significantly reduce medical costs associated with the treatment of these infections. Public health campaigns and immunization programs worldwide emphasize the importance of these vaccines in controlling outbreaks and protecting at-risk populations.

How Does Global Health Initiatives Influence the Demand for Meningococcal Vaccines?

Global health initiatives significantly influence the demand for meningococcal vaccines. Programs coordinated by organizations such as the World Health Organization (WHO) and the Global Alliance for Vaccines and Immunization (GAVI) aim to increase vaccine access in underserved areas, particularly in sub-Saharan Africa where the disease burden is high. These initiatives help in the widespread administration of meningococcal vaccines, thus controlling the spread of the disease. Moreover, outbreaks of meningococcal disease often prompt immediate responses in terms of mass vaccination campaigns, showcasing the direct impact of epidemiological trends on vaccine demand. The growing awareness of meningococcal disease and the proven effectiveness of vaccines are also driving their uptake in both developing and developed countries.

What Are the Scientific and Technological Progressions Impacting Meningococcal Vaccines?

Scientific and technological progressions are enhancing the effectiveness and reach of meningococcal vaccines. Advances in biotechnology have enabled the development of conjugate vaccines, which offer longer-lasting immunity and a stronger immune response in younger populations. Research into new vaccine formulations continues to expand the protection against additional strains of the meningococcus bacterium. Technological improvements in vaccine production and storage also make it possible to extend the distribution networks, reaching remote areas more effectively. These advancements are critical for maintaining global supply chains, especially in low-resource settings, and improving overall vaccination rates, which are essential for eradicating meningococcal disease worldwide.

What Drives the Growth in the Meningococcal Vaccines Market?

The growth in the meningococcal vaccines market is driven by several factors, including increased global healthcare initiatives, rising awareness of the disease, and the implementation of national immunization programs. Technological advancements that improve vaccine efficacy and production capabilities also play a significant role. The push for higher immunization coverage, combined with public health responses to outbreaks, further stimulates demand for these vaccines. Additionally, government funding and international support for vaccine research and development are crucial for addressing the evolving pathogen landscape, ensuring continued adaptation and protection against new strains. As awareness and healthcare infrastructure improve, particularly in developing nations, the demand for meningococcal vaccines is expected to rise, continuing to drive market expansion.

SCOPE OF STUDY:

The report analyzes the Meningococcal Vaccines market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Quadrivalent, Bivalent, Other Types); Serotype (Serotype A, Serotype B, Serotype C, Serotype W-135, Other Serotypes); Age Group (Infants (Up to 2 years), Children (Above 2 years) & Adults)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 42 Featured) -

• Baxter International, Inc.
• Bio-Med Pvt., Ltd.
• GlaxoSmithKline PLC
• Pfizer, Inc.
• Sanofi SA
• Serum Institute of India Pvt., Ltd.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Meningococcal Vaccines - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Global Incidence of Meningococcal Disease Spurs Demand for Vaccines
  • Advancements in Vaccine Technology Propel Development of New Meningococcal Vaccines
  • Increased Government Funding Enhances Accessibility of Meningococcal Vaccines
  • Global Health Initiatives Boost Immunization Rates for Meningococcal Disease
  • Public Awareness Campaigns Amplify Uptake of Meningococcal Vaccines
  • Expansion of Immunization Programs in Developing Regions Drives Vaccine Adoption
  • Collaborations Between Global Health Bodies and Vaccine Developers Enhance Reach
  • Outbreak Response Strategies Bolster Short-Term Demand for Meningococcal Vaccines
  • Travel Regulations Mandate Meningococcal Vaccination, Driving Market Growth
  • Adult Vaccination Programs Expand Beyond Traditional Pediatric Use
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Meningococcal Vaccines Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Meningococcal Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 3: World 6-Year Perspective for Meningococcal Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2025 & 2030
  • TABLE 4: World Recent Past, Current & Future Analysis for Quadrivalent by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 5: World 6-Year Perspective for Quadrivalent by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 6: World Recent Past, Current & Future Analysis for Bivalent by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 7: World 6-Year Perspective for Bivalent by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 9: World 6-Year Perspective for Other Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 10: World Recent Past, Current & Future Analysis for Serotype A by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 11: World 6-Year Perspective for Serotype A by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 12: World Recent Past, Current & Future Analysis for Serotype B by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 13: World 6-Year Perspective for Serotype B by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Serotype C by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 15: World 6-Year Perspective for Serotype C by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 16: World Recent Past, Current & Future Analysis for Serotype W-135 by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 17: World 6-Year Perspective for Serotype W-135 by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 18: World Recent Past, Current & Future Analysis for Other Serotypes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 19: World 6-Year Perspective for Other Serotypes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Infants (Up to 2 years) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 21: World 6-Year Perspective for Infants (Up to 2 years) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 22: World Recent Past, Current & Future Analysis for Children (Above 2 years) & Adults by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 23: World 6-Year Perspective for Children (Above 2 years) & Adults by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Meningococcal Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 24: USA Recent Past, Current & Future Analysis for Meningococcal Vaccines by Type - Quadrivalent, Bivalent and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 25: USA 6-Year Perspective for Meningococcal Vaccines by Type - Percentage Breakdown of Value Sales for Quadrivalent, Bivalent and Other Types for the Years 2025 & 2030
  • TABLE 26: USA Recent Past, Current & Future Analysis for Meningococcal Vaccines by Serotype - Serotype A, Serotype B, Serotype C, Serotype W-135 and Other Serotypes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 27: USA 6-Year Perspective for Meningococcal Vaccines by Serotype - Percentage Breakdown of Value Sales for Serotype A, Serotype B, Serotype C, Serotype W-135 and Other Serotypes for the Years 2025 & 2030
  • TABLE 28: USA Recent Past, Current & Future Analysis for Meningococcal Vaccines by Age Group - Infants (Up to 2 years) and Children (Above 2 years) & Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 29: USA 6-Year Perspective for Meningococcal Vaccines by Age Group - Percentage Breakdown of Value Sales for Infants (Up to 2 years) and Children (Above 2 years) & Adults for the Years 2025 & 2030
• CANADA
  • TABLE 30: Canada Recent Past, Current & Future Analysis for Meningococcal Vaccines by Type - Quadrivalent, Bivalent and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 31: Canada 6-Year Perspective for Meningococcal Vaccines by Type - Percentage Breakdown of Value Sales for Quadrivalent, Bivalent and Other Types for the Years 2025 & 2030
  • TABLE 32: Canada Recent Past, Current & Future Analysis for Meningococcal Vaccines by Serotype - Serotype A, Serotype B, Serotype C, Serotype W-135 and Other Serotypes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 33: Canada 6-Year Perspective for Meningococcal Vaccines by Serotype - Percentage Breakdown of Value Sales for Serotype A, Serotype B, Serotype C, Serotype W-135 and Other Serotypes for the Years 2025 & 2030
  • TABLE 34: Canada Recent Past, Current & Future Analysis for Meningococcal Vaccines by Age Group - Infants (Up to 2 years) and Children (Above 2 years) & Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 35: Canada 6-Year Perspective for Meningococcal Vaccines by Age Group - Percentage Breakdown of Value Sales for Infants (Up to 2 years) and Children (Above 2 years) & Adults for the Years 2025 & 2030
• JAPAN
  • Meningococcal Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 36: Japan Recent Past, Current & Future Analysis for Meningococcal Vaccines by Type - Quadrivalent, Bivalent and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 37: Japan 6-Year Perspective for Meningococcal Vaccines by Type - Percentage Breakdown of Value Sales for Quadrivalent, Bivalent and Other Types for the Years 2025 & 2030
  • TABLE 38: Japan Recent Past, Current & Future Analysis for Meningococcal Vaccines by Serotype - Serotype A, Serotype B, Serotype C, Serotype W-135 and Other Serotypes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 39: Japan 6-Year Perspective for Meningococcal Vaccines by Serotype - Percentage Breakdown of Value Sales for Serotype A, Serotype B, Serotype C, Serotype W-135 and Other Serotypes for the Years 2025 & 2030
  • TABLE 40: Japan Recent Past, Current & Future Analysis for Meningococcal Vaccines by Age Group - Infants (Up to 2 years) and Children (Above 2 years) & Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 41: Japan 6-Year Perspective for Meningococcal Vaccines by Age Group - Percentage Breakdown of Value Sales for Infants (Up to 2 years) and Children (Above 2 years) & Adults for the Years 2025 & 2030
• CHINA
  • Meningococcal Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 42: China Recent Past, Current & Future Analysis for Meningococcal Vaccines by Type - Quadrivalent, Bivalent and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 43: China 6-Year Perspective for Meningococcal Vaccines by Type - Percentage Breakdown of Value Sales for Quadrivalent, Bivalent and Other Types for the Years 2025 & 2030
  • TABLE 44: China Recent Past, Current & Future Analysis for Meningococcal Vaccines by Serotype - Serotype A, Serotype B, Serotype C, Serotype W-135 and Other Serotypes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 45: China 6-Year Perspective for Meningococcal Vaccines by Serotype - Percentage Breakdown of Value Sales for Serotype A, Serotype B, Serotype C, Serotype W-135 and Other Serotypes for the Years 2025 & 2030
  • TABLE 46: China Recent Past, Current & Future Analysis for Meningococcal Vaccines by Age Group - Infants (Up to 2 years) and Children (Above 2 years) & Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 47: China 6-Year Perspective for Meningococcal Vaccines by Age Group - Percentage Breakdown of Value Sales for Infants (Up to 2 years) and Children (Above 2 years) & Adults for the Years 2025 & 2030
• EUROPE
  • Meningococcal Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 48: Europe Recent Past, Current & Future Analysis for Meningococcal Vaccines by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 49: Europe 6-Year Perspective for Meningococcal Vaccines by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2025 & 2030
  • TABLE 50: Europe Recent Past, Current & Future Analysis for Meningococcal Vaccines by Type - Quadrivalent, Bivalent and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 51: Europe 6-Year Perspective for Meningococcal Vaccines by Type - Percentage Breakdown of Value Sales for Quadrivalent, Bivalent and Other Types for the Years 2025 & 2030
  • TABLE 52: Europe Recent Past, Current & Future Analysis for Meningococcal Vaccines by Serotype - Serotype A, Serotype B, Serotype C, Serotype W-135 and Other Serotypes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 53: Europe 6-Year Perspective for Meningococcal Vaccines by Serotype - Percentage Breakdown of Value Sales for Serotype A, Serotype B, Serotype C, Serotype W-135 and Other Serotypes for the Years 2025 & 2030
  • TABLE 54: Europe Recent Past, Current & Future Analysis for Meningococcal Vaccines by Age Group - Infants (Up to 2 years) and Children (Above 2 years) & Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 55: Europe 6-Year Perspective for Meningococcal Vaccines by Age Group - Percentage Breakdown of Value Sales for Infants (Up to 2 years) and Children (Above 2 years) & Adults for the Years 2025 & 2030
• FRANCE
  • Meningococcal Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 56: France Recent Past, Current & Future Analysis for Meningococcal Vaccines by Type - Quadrivalent, Bivalent and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 57: France 6-Year Perspective for Meningococcal Vaccines by Type - Percentage Breakdown of Value Sales for Quadrivalent, Bivalent and Other Types for the Years 2025 & 2030
  • TABLE 58: France Recent Past, Current & Future Analysis for Meningococcal Vaccines by Serotype - Serotype A, Serotype B, Serotype C, Serotype W-135 and Other Serotypes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 59: France 6-Year Perspective for Meningococcal Vaccines by Serotype - Percentage Breakdown of Value Sales for Serotype A, Serotype B, Serotype C, Serotype W-135 and Other Serotypes for the Years 2025 & 2030
  • TABLE 60: France Recent Past, Current & Future Analysis for Meningococcal Vaccines by Age Group - Infants (Up to 2 years) and Children (Above 2 years) & Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 61: France 6-Year Perspective for Meningococcal Vaccines by Age Group - Percentage Breakdown of Value Sales for Infants (Up to 2 years) and Children (Above 2 years) & Adults for the Years 2025 & 2030
• GERMANY
  • Meningococcal Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 62: Germany Recent Past, Current & Future Analysis for Meningococcal Vaccines by Type - Quadrivalent, Bivalent and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 63: Germany 6-Year Perspective for Meningococcal Vaccines by Type - Percentage Breakdown of Value Sales for Quadrivalent, Bivalent and Other Types for the Years 2025 & 2030
  • TABLE 64: Germany Recent Past, Current & Future Analysis for Meningococcal Vaccines by Serotype - Serotype A, Serotype B, Serotype C, Serotype W-135 and Other Serotypes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 65: Germany 6-Year Perspective for Meningococcal Vaccines by Serotype - Percentage Breakdown of Value Sales for Serotype A, Serotype B, Serotype C, Serotype W-135 and Other Serotypes for the Years 2025 & 2030
  • TABLE 66: Germany Recent Past, Current & Future Analysis for Meningococcal Vaccines by Age Group - Infants (Up to 2 years) and Children (Above 2 years) & Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 67: Germany 6-Year Perspective for Meningococcal Vaccines by Age Group - Percentage Breakdown of Value Sales for Infants (Up to 2 years) and Children (Above 2 years) & Adults for the Years 2025 & 2030
• ITALY
  • TABLE 68: Italy Recent Past, Current & Future Analysis for Meningococcal Vaccines by Type - Quadrivalent, Bivalent and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 69: Italy 6-Year Perspective for Meningococcal Vaccines by Type - Percentage Breakdown of Value Sales for Quadrivalent, Bivalent and Other Types for the Years 2025 & 2030
  • TABLE 70: Italy Recent Past, Current & Future Analysis for Meningococcal Vaccines by Serotype - Serotype A, Serotype B, Serotype C, Serotype W-135 and Other Serotypes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 71: Italy 6-Year Perspective for Meningococcal Vaccines by Serotype - Percentage Breakdown of Value Sales for Serotype A, Serotype B, Serotype C, Serotype W-135 and Other Serotypes for the Years 2025 & 2030
  • TABLE 72: Italy Recent Past, Current & Future Analysis for Meningococcal Vaccines by Age Group - Infants (Up to 2 years) and Children (Above 2 years) & Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 73: Italy 6-Year Perspective for Meningococcal Vaccines by Age Group - Percentage Breakdown of Value Sales for Infants (Up to 2 years) and Children (Above 2 years) & Adults for the Years 2025 & 2030
• UNITED KINGDOM
  • Meningococcal Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 74: UK Recent Past, Current & Future Analysis for Meningococcal Vaccines by Type - Quadrivalent, Bivalent and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 75: UK 6-Year Perspective for Meningococcal Vaccines by Type - Percentage Breakdown of Value Sales for Quadrivalent, Bivalent and Other Types for the Years 2025 & 2030
  • TABLE 76: UK Recent Past, Current & Future Analysis for Meningococcal Vaccines by Serotype - Serotype A, Serotype B, Serotype C, Serotype W-135 and Other Serotypes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 77: UK 6-Year Perspective for Meningococcal Vaccines by Serotype - Percentage Breakdown of Value Sales for Serotype A, Serotype B, Serotype C, Serotype W-135 and Other Serotypes for the Years 2025 & 2030
  • TABLE 78: UK Recent Past, Current & Future Analysis for Meningococcal Vaccines by Age Group - Infants (Up to 2 years) and Children (Above 2 years) & Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 79: UK 6-Year Perspective for Meningococcal Vaccines by Age Group - Percentage Breakdown of Value Sales for Infants (Up to 2 years) and Children (Above 2 years) & Adults for the Years 2025 & 2030
• REST OF EUROPE
  • TABLE 80: Rest of Europe Recent Past, Current & Future Analysis for Meningococcal Vaccines by Type - Quadrivalent, Bivalent and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 81: Rest of Europe 6-Year Perspective for Meningococcal Vaccines by Type - Percentage Breakdown of Value Sales for Quadrivalent, Bivalent and Other Types for the Years 2025 & 2030
  • TABLE 82: Rest of Europe Recent Past, Current & Future Analysis for Meningococcal Vaccines by Serotype - Serotype A, Serotype B, Serotype C, Serotype W-135 and Other Serotypes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 83: Rest of Europe 6-Year Perspective for Meningococcal Vaccines by Serotype - Percentage Breakdown of Value Sales for Serotype A, Serotype B, Serotype C, Serotype W-135 and Other Serotypes for the Years 2025 & 2030
  • TABLE 84: Rest of Europe Recent Past, Current & Future Analysis for Meningococcal Vaccines by Age Group - Infants (Up to 2 years) and Children (Above 2 years) & Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 85: Rest of Europe 6-Year Perspective for Meningococcal Vaccines by Age Group - Percentage Breakdown of Value Sales for Infants (Up to 2 years) and Children (Above 2 years) & Adults for the Years 2025 & 2030
• ASIA-PACIFIC
  • Meningococcal Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 86: Asia-Pacific Recent Past, Current & Future Analysis for Meningococcal Vaccines by Type - Quadrivalent, Bivalent and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 87: Asia-Pacific 6-Year Perspective for Meningococcal Vaccines by Type - Percentage Breakdown of Value Sales for Quadrivalent, Bivalent and Other Types for the Years 2025 & 2030
  • TABLE 88: Asia-Pacific Recent Past, Current & Future Analysis for Meningococcal Vaccines by Serotype - Serotype A, Serotype B, Serotype C, Serotype W-135 and Other Serotypes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 89: Asia-Pacific 6-Year Perspective for Meningococcal Vaccines by Serotype - Percentage Breakdown of Value Sales for Serotype A, Serotype B, Serotype C, Serotype W-135 and Other Serotypes for the Years 2025 & 2030
  • TABLE 90: Asia-Pacific Recent Past, Current & Future Analysis for Meningococcal Vaccines by Age Group - Infants (Up to 2 years) and Children (Above 2 years) & Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 91: Asia-Pacific 6-Year Perspective for Meningococcal Vaccines by Age Group - Percentage Breakdown of Value Sales for Infants (Up to 2 years) and Children (Above 2 years) & Adults for the Years 2025 & 2030
• REST OF WORLD
  • TABLE 92: Rest of World Recent Past, Current & Future Analysis for Meningococcal Vaccines by Type - Quadrivalent, Bivalent and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 93: Rest of World 6-Year Perspective for Meningococcal Vaccines by Type - Percentage Breakdown of Value Sales for Quadrivalent, Bivalent and Other Types for the Years 2025 & 2030
  • TABLE 94: Rest of World Recent Past, Current & Future Analysis for Meningococcal Vaccines by Serotype - Serotype A, Serotype B, Serotype C, Serotype W-135 and Other Serotypes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 95: Rest of World 6-Year Perspective for Meningococcal Vaccines by Serotype - Percentage Breakdown of Value Sales for Serotype A, Serotype B, Serotype C, Serotype W-135 and Other Serotypes for the Years 2025 & 2030
  • TABLE 96: Rest of World Recent Past, Current & Future Analysis for Meningococcal Vaccines by Age Group - Infants (Up to 2 years) and Children (Above 2 years) & Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 97: Rest of World 6-Year Perspective for Meningococcal Vaccines by Age Group - Percentage Breakdown of Value Sales for Infants (Up to 2 years) and Children (Above 2 years) & Adults for the Years 2025 & 2030

IV. COMPETITION